Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Preferred Stock Liabilities (2019 - 2020)

Historic Preferred Stock Liabilities for Keros Therapeutics (KROS) over the last 2 years, with Q1 2020 value amounting to $75.7 million.

  • Keros Therapeutics' Preferred Stock Liabilities rose 66556.47% to $75.7 million in Q1 2020 from the same period last year, while for Mar 2020 it was $75.7 million, marking a year-over-year increase of 66556.47%. This contributed to the annual value of $19.9 million for FY2019, which is N/A changed from last year.
  • As of Q1 2020, Keros Therapeutics' Preferred Stock Liabilities stood at $75.7 million, which was up 66556.47% from $19.9 million recorded in Q4 2019.
  • Keros Therapeutics' 5-year Preferred Stock Liabilities high stood at $75.7 million for Q1 2020, and its period low was $9.9 million during Q1 2019.